Promising immunotherapy trial aims to replace harsh chemo for kids with relapsed leukemia
NCT ID NCT07476729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests two immunotherapy drugs, inotuzumab and blinatumomab, in 750 children with relapsed B-cell acute lymphoblastic leukemia. The goal is to replace toxic chemotherapy with targeted, less harmful treatments to improve survival and reduce side effects. Participants are children aged 1 to 21 with a first relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inotuzumab ozogamicin and blinatumomab
What this could lead to
If successful, this could establish less toxic immunotherapy as the new standard of care for children with relapsed B-cell ALL, improving survival and reducing side effects.
What could go wrong
This is a large phase 3 trial, but it hasn't started recruiting yet. The new drugs may not work better than current treatments, and there are risks like severe immune reactions or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acıbadem University
Istanbul, 34752, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de NICE, Hôpital L'ARCHET
Nice, 06202, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fakultni Nemocnice V Motole
Prague, 150 00, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundeni Clinical Institute, Pediatric Clinic Fundeni
Bucharest, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ghent University Hospital
Ghent, B-9000, Belgium
Contact
-
HUS Helsinki University Hospital
Helsinki, FIN-00290, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Português de Oncologia de Lisboa
Lisbon, 1099-023, Portugal
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karolinska University Hospital
Solna, 171 64, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale Pediatrico Bambino Gesu
Rome, 00165, Italy
Contact
-
Prinses Máxima Centrum
Utrecht, 3584 CS, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Semmelweis University
Budapest, 1094, Hungary
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Anna Kinderspital GmbH
Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital
Tel Aviv, 64239, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Children's Hospital
Zurich, 8032, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Wroclaw
Wroclaw, 50 354, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Univerzity Komenského a Národného
Bratislava, 833 40, Slovakia
Contact Phone: •••-•••-•••• Email: •••••@•••••